Goldman Sachs analyst Rajan Sharma introduced a Buy rating and $13.50 price target for Immatics (IMTX) after previously being Not Rated on the early-stage biotech company. The firm is positive on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback